JP2007531753A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007531753A5 JP2007531753A5 JP2007506483A JP2007506483A JP2007531753A5 JP 2007531753 A5 JP2007531753 A5 JP 2007531753A5 JP 2007506483 A JP2007506483 A JP 2007506483A JP 2007506483 A JP2007506483 A JP 2007506483A JP 2007531753 A5 JP2007531753 A5 JP 2007531753A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- piperidin
- isopropyl
- ylmethyl
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 claims 80
- 150000001875 compounds Chemical class 0.000 claims 50
- -1 —C 3-7 cycloalkyl Chemical group 0.000 claims 47
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 44
- 229910052757 nitrogen Inorganic materials 0.000 claims 25
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 24
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 24
- 229910052799 carbon Inorganic materials 0.000 claims 20
- 125000005842 heteroatom Chemical group 0.000 claims 20
- 229910052760 oxygen Inorganic materials 0.000 claims 20
- 229910052717 sulfur Inorganic materials 0.000 claims 20
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 16
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 16
- 125000004076 pyridyl group Chemical group 0.000 claims 16
- 125000000168 pyrrolyl group Chemical group 0.000 claims 16
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 13
- 125000002541 furyl group Chemical group 0.000 claims 12
- 125000005843 halogen group Chemical group 0.000 claims 12
- 125000000623 heterocyclic group Chemical class 0.000 claims 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 12
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 12
- 125000001544 thienyl group Chemical group 0.000 claims 12
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 10
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical group C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 10
- 125000003386 piperidinyl group Chemical group 0.000 claims 10
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims 8
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 claims 8
- 125000003342 alkenyl group Chemical group 0.000 claims 8
- 125000000304 alkynyl group Chemical group 0.000 claims 8
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims 8
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 8
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 8
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 8
- 125000002950 monocyclic group Chemical group 0.000 claims 8
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 8
- 125000001424 substituent group Chemical group 0.000 claims 8
- 206010016256 fatigue Diseases 0.000 claims 7
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 6
- 206010041349 Somnolence Diseases 0.000 claims 5
- 239000004480 active ingredient Substances 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 claims 4
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 4
- 208000032140 Sleepiness Diseases 0.000 claims 4
- 125000003725 azepanyl group Chemical group 0.000 claims 4
- 125000005605 benzo group Chemical group 0.000 claims 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 4
- 229960001340 histamine Drugs 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 125000002757 morpholinyl group Chemical group 0.000 claims 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 4
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 claims 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 4
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 4
- OIAJPFFTFXBSJX-UHFFFAOYSA-N (4-propan-2-ylpiperazin-1-yl)-[6-(4-propan-2-ylpiperazin-1-yl)pyridin-3-yl]methanone Chemical compound C1CN(C(C)C)CCN1C(=O)C1=CC=C(N2CCN(CC2)C(C)C)N=C1 OIAJPFFTFXBSJX-UHFFFAOYSA-N 0.000 claims 3
- YPSYERLUIKJCIR-UHFFFAOYSA-N 2-(4-piperidin-1-ylbut-1-ynyl)-5-(piperidin-1-ylmethyl)pyridine Chemical compound C=1C=C(CN2CCCCC2)C=NC=1C#CCCN1CCCCC1 YPSYERLUIKJCIR-UHFFFAOYSA-N 0.000 claims 3
- CHOVROLMBZWCJS-UHFFFAOYSA-N 2-(4-piperidin-1-ylbut-1-ynyl)-6-(piperidin-1-ylmethyl)pyridine Chemical compound C=1C=CC(CN2CCCCC2)=NC=1C#CCCN1CCCCC1 CHOVROLMBZWCJS-UHFFFAOYSA-N 0.000 claims 3
- WKWXSSAQMKWZEO-UHFFFAOYSA-N 2-(piperidin-1-ylmethyl)-5-(3-piperidin-1-ylpropoxy)pyridine Chemical compound C1CCCCN1CCCOC(C=N1)=CC=C1CN1CCCCC1 WKWXSSAQMKWZEO-UHFFFAOYSA-N 0.000 claims 3
- WMCAAXRHPIJBKV-UHFFFAOYSA-N 3-(4-piperidin-1-ylbut-1-ynyl)-5-(piperidin-1-ylmethyl)pyridine Chemical compound C=1N=CC(CN2CCCCC2)=CC=1C#CCCN1CCCCC1 WMCAAXRHPIJBKV-UHFFFAOYSA-N 0.000 claims 3
- HBRMMMIKWGTGEY-UHFFFAOYSA-N 5-(piperidin-4-ylmethyl)-3-(3-piperidin-1-ylpropoxy)-1,2-oxazole Chemical compound C1CCCCN1CCCOC(=NO1)C=C1CC1CCNCC1 HBRMMMIKWGTGEY-UHFFFAOYSA-N 0.000 claims 3
- GYHPIGHVWUMTDM-UHFFFAOYSA-N [2-(2-piperidin-1-ylethylamino)pyridin-4-yl]-(4-propan-2-ylpiperazin-1-yl)methanone Chemical compound C1CN(C(C)C)CCN1C(=O)C1=CC=NC(NCCN2CCCCC2)=C1 GYHPIGHVWUMTDM-UHFFFAOYSA-N 0.000 claims 3
- USOUXPUSQBUUOL-UHFFFAOYSA-N [5-(piperidin-1-ylmethyl)pyrazin-2-yl]-(4-propan-2-ylpiperazin-1-yl)methanone Chemical compound C1CN(C(C)C)CCN1C(=O)C(N=C1)=CN=C1CN1CCCCC1 USOUXPUSQBUUOL-UHFFFAOYSA-N 0.000 claims 3
- QARLWQQWNLVURD-UHFFFAOYSA-N [5-(piperidin-1-ylmethyl)pyridin-2-yl]-(4-propan-2-ylpiperazin-1-yl)methanone Chemical compound C1CN(C(C)C)CCN1C(=O)C(N=C1)=CC=C1CN1CCCCC1 QARLWQQWNLVURD-UHFFFAOYSA-N 0.000 claims 3
- AOHGNUVYWCFCAB-UHFFFAOYSA-N [6-(2-piperidin-1-ylethylamino)pyridin-3-yl]-(4-propan-2-ylpiperazin-1-yl)methanone Chemical compound C1CN(C(C)C)CCN1C(=O)C(C=N1)=CC=C1NCCN1CCCCC1 AOHGNUVYWCFCAB-UHFFFAOYSA-N 0.000 claims 3
- UPLGWHHVDUGCBV-UHFFFAOYSA-N [6-(4-methylpiperazin-1-yl)pyridin-3-yl]-(4-propan-2-ylpiperazin-1-yl)methanone Chemical compound C1CN(C(C)C)CCN1C(=O)C1=CC=C(N2CCN(C)CC2)N=C1 UPLGWHHVDUGCBV-UHFFFAOYSA-N 0.000 claims 3
- HGMKONUWLRPGDN-UHFFFAOYSA-N [6-(piperidin-1-ylmethyl)pyridin-3-yl]-(4-propan-2-ylpiperazin-1-yl)methanone Chemical compound C1CN(C(C)C)CCN1C(=O)C(C=N1)=CC=C1CN1CCCCC1 HGMKONUWLRPGDN-UHFFFAOYSA-N 0.000 claims 3
- QKZQWVNCJGIHKR-UHFFFAOYSA-N [6-[2-(diethylamino)ethyl-methylamino]pyridin-3-yl]-(4-propan-2-ylpiperazin-1-yl)methanone Chemical compound C1=NC(N(C)CCN(CC)CC)=CC=C1C(=O)N1CCN(C(C)C)CC1 QKZQWVNCJGIHKR-UHFFFAOYSA-N 0.000 claims 3
- 208000010877 cognitive disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 201000000980 schizophrenia Diseases 0.000 claims 3
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 claims 3
- CKXAANQKPSPHLE-UHFFFAOYSA-N 2-methoxy-n-[[6-(4-piperidin-1-ylbut-1-ynyl)pyridin-2-yl]methyl]ethanamine Chemical compound COCCNCC1=CC=CC(C#CCCN2CCCCC2)=N1 CKXAANQKPSPHLE-UHFFFAOYSA-N 0.000 claims 2
- AKESFWSNMOFOQC-UHFFFAOYSA-N 4-[[5-(3-piperidin-1-ylpropoxy)pyridin-2-yl]methyl]morpholine Chemical compound C1CCCCN1CCCOC(C=N1)=CC=C1CN1CCOCC1 AKESFWSNMOFOQC-UHFFFAOYSA-N 0.000 claims 2
- FWRQHCPMFYKQDK-UHFFFAOYSA-N 4-[[5-(4-piperidin-1-ylbut-1-ynyl)pyridin-3-yl]methyl]morpholine Chemical compound C=1N=CC(CN2CCOCC2)=CC=1C#CCCN1CCCCC1 FWRQHCPMFYKQDK-UHFFFAOYSA-N 0.000 claims 2
- WYTHXDDMVDKEGH-UHFFFAOYSA-N 4-[[6-(4-piperidin-1-ylbut-1-ynyl)pyridin-2-yl]methyl]morpholine Chemical compound C=1C=CC(CN2CCOCC2)=NC=1C#CCCN1CCCCC1 WYTHXDDMVDKEGH-UHFFFAOYSA-N 0.000 claims 2
- QBLLOOKBLTTXHB-UHFFFAOYSA-N 4-fluoropiperidine Chemical compound FC1CCNCC1 QBLLOOKBLTTXHB-UHFFFAOYSA-N 0.000 claims 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 206010028735 Nasal congestion Diseases 0.000 claims 2
- 206010062519 Poor quality sleep Diseases 0.000 claims 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 2
- IHVNECQDFNGHMR-UHFFFAOYSA-N [5-(morpholin-4-ylmethyl)pyrazin-2-yl]-(4-propan-2-ylpiperazin-1-yl)methanone Chemical compound C1CN(C(C)C)CCN1C(=O)C(N=C1)=CN=C1CN1CCOCC1 IHVNECQDFNGHMR-UHFFFAOYSA-N 0.000 claims 2
- SMTAOJXZSKNKPY-UHFFFAOYSA-N [6-(2-morpholin-4-ylethylamino)pyridin-3-yl]-(4-propan-2-ylpiperazin-1-yl)methanone Chemical compound C1CN(C(C)C)CCN1C(=O)C(C=N1)=CC=C1NCCN1CCOCC1 SMTAOJXZSKNKPY-UHFFFAOYSA-N 0.000 claims 2
- FXPLHFGBSQNNAN-UHFFFAOYSA-N [6-(morpholin-4-ylmethyl)pyridin-3-yl]-(4-propan-2-ylpiperazin-1-yl)methanone Chemical compound C1CN(C(C)C)CCN1C(=O)C(C=N1)=CC=C1CN1CCOCC1 FXPLHFGBSQNNAN-UHFFFAOYSA-N 0.000 claims 2
- 201000010105 allergic rhinitis Diseases 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 230000006735 deficit Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 150000004677 hydrates Chemical class 0.000 claims 2
- 208000013403 hyperactivity Diseases 0.000 claims 2
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 201000003631 narcolepsy Diseases 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 2
- 230000037321 sleepiness Effects 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical group C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- HURMQHJALYVPRY-UHFFFAOYSA-N (4-propan-2-ylpiperazin-1-yl)-[6-(2-pyridin-2-ylethylamino)pyridin-3-yl]methanone Chemical compound C1CN(C(C)C)CCN1C(=O)C(C=N1)=CC=C1NCCC1=CC=CC=N1 HURMQHJALYVPRY-UHFFFAOYSA-N 0.000 claims 1
- LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical compound CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 claims 1
- YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 claims 1
- UUUVBWRORGAQIW-UHFFFAOYSA-N 2-methoxy-n-[[3-(3-piperidin-1-ylpropoxy)-1,2-oxazol-5-yl]methyl]ethanamine Chemical compound O1C(CNCCOC)=CC(OCCCN2CCCCC2)=N1 UUUVBWRORGAQIW-UHFFFAOYSA-N 0.000 claims 1
- ADLWZDMYNOGVRT-UHFFFAOYSA-N 4-[[3-(3-piperidin-1-ylpropoxy)-1,2-oxazol-5-yl]methyl]morpholine Chemical compound C1CCCCN1CCCOC(=NO1)C=C1CN1CCOCC1 ADLWZDMYNOGVRT-UHFFFAOYSA-N 0.000 claims 1
- MJFRUZWZLAZUGG-UHFFFAOYSA-N 5-(piperidin-1-ylmethyl)-2-(3-piperidin-1-ylpropoxy)pyridine Chemical compound C1CCCCN1CCCOC(N=C1)=CC=C1CN1CCCCC1 MJFRUZWZLAZUGG-UHFFFAOYSA-N 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 206010002091 Anaesthesia Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims 1
- 208000017164 Chronobiology disease Diseases 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 claims 1
- 206010013654 Drug abuse Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000008238 Muscle Spasticity Diseases 0.000 claims 1
- 229910002651 NO3 Inorganic materials 0.000 claims 1
- 208000007920 Neurogenic Inflammation Diseases 0.000 claims 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- 201000001880 Sexual dysfunction Diseases 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 claims 1
- OZNWGBRNCLPCEK-UHFFFAOYSA-N [2-(2-piperidin-1-ylethylamino)pyridin-3-yl]-(4-propan-2-ylpiperazin-1-yl)methanone Chemical compound C1CN(C(C)C)CCN1C(=O)C1=CC=CN=C1NCCN1CCCCC1 OZNWGBRNCLPCEK-UHFFFAOYSA-N 0.000 claims 1
- CYKIJOQYHLZFST-UHFFFAOYSA-N [6-(piperidin-1-ylmethyl)pyridin-3-yl]-(4-propan-2-ylpiperazin-1-yl)methanethione Chemical compound C1CN(C(C)C)CCN1C(=S)C(C=N1)=CC=C1CN1CCCCC1 CYKIJOQYHLZFST-UHFFFAOYSA-N 0.000 claims 1
- 229940022663 acetate Drugs 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 230000037005 anaesthesia Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 206010008129 cerebral palsy Diseases 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 208000027744 congestion Diseases 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 208000002173 dizziness Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- VQCPJGLXPRKLEI-UHFFFAOYSA-N ethyl 4-[5-(4-propan-2-ylpiperazine-1-carbonyl)pyridin-2-yl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C1=CC=C(C(=O)N2CCN(CC2)C(C)C)C=N1 VQCPJGLXPRKLEI-UHFFFAOYSA-N 0.000 claims 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims 1
- 239000000938 histamine H1 antagonist Substances 0.000 claims 1
- 230000013632 homeostatic process Effects 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 claims 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 1
- 238000002483 medication Methods 0.000 claims 1
- 230000006984 memory degeneration Effects 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 208000023060 memory loss Diseases 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- 229960001165 modafinil Drugs 0.000 claims 1
- 239000003068 molecular probe Substances 0.000 claims 1
- 201000003152 motion sickness Diseases 0.000 claims 1
- 125000005487 naphthalate group Chemical group 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- 229940049964 oleate Drugs 0.000 claims 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 1
- 229940039748 oxalate Drugs 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 238000002600 positron emission tomography Methods 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 208000012201 sexual and gender identity disease Diseases 0.000 claims 1
- 208000015891 sexual disease Diseases 0.000 claims 1
- 231100000872 sexual dysfunction Toxicity 0.000 claims 1
- 238000002603 single-photon emission computed tomography Methods 0.000 claims 1
- 201000002859 sleep apnea Diseases 0.000 claims 1
- 208000018198 spasticity Diseases 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- 229940095064 tartrate Drugs 0.000 claims 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 1
- 229940070710 valerate Drugs 0.000 claims 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims 1
- 0 *NCCB*C(C(CC1)C*CCC1ON(*)*)N(*)* Chemical compound *NCCB*C(C(CC1)C*CCC1ON(*)*)N(*)* 0.000 description 2
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55795904P | 2004-03-31 | 2004-03-31 | |
| PCT/US2005/010570 WO2005097751A2 (en) | 2004-03-31 | 2005-03-31 | Non-imidazole heterocyclic compounds as histamine h3-receptor ligands |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007531753A JP2007531753A (ja) | 2007-11-08 |
| JP2007531753A5 true JP2007531753A5 (enExample) | 2008-02-07 |
Family
ID=34965686
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007506483A Withdrawn JP2007531753A (ja) | 2004-03-31 | 2005-03-31 | 非イミダゾール系複素環式化合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US7423147B2 (enExample) |
| EP (1) | EP1761496A2 (enExample) |
| JP (1) | JP2007531753A (enExample) |
| CN (1) | CN1972914A (enExample) |
| AU (1) | AU2005230902A1 (enExample) |
| CA (1) | CA2561791A1 (enExample) |
| MX (1) | MXPA06011414A (enExample) |
| WO (1) | WO2005097751A2 (enExample) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2561791A1 (en) * | 2004-03-31 | 2005-10-20 | Janssen Pharmaceutica, N.V. | Non-imidazole heterocyclic compounds |
| EA015555B1 (ru) * | 2006-05-30 | 2011-08-30 | Янссен Фармацевтика Н.В. | Замещенные пиридиламидные соединения в качестве модуляторов гистаминового h-рецептора |
| AU2007265238A1 (en) * | 2006-06-29 | 2008-01-03 | Janssen Pharmaceutica N.V. | Substituted benzamide modulators of the histamine H3 receptor |
| FR2903904A1 (fr) * | 2006-07-21 | 2008-01-25 | Bioprojet Soc Civ Ile | Association de modafinil et d'un antagoniste ou agoniste inverse du recepteur h3 |
| BRPI0714793A2 (pt) | 2006-08-03 | 2015-06-16 | Tufts College | Análogos de niacina não enrubecedores e método de uso dos mesmos. |
| TW200827346A (en) * | 2006-11-03 | 2008-07-01 | Astrazeneca Ab | Chemical compounds |
| WO2008145681A2 (en) | 2007-05-31 | 2008-12-04 | Boehringer Ingelheim International Gmbh | Ccr2 receptor antagonists and uses thereof |
| CA2705502C (en) | 2007-11-13 | 2016-01-26 | Taisho Pharmaceutical Co., Ltd. | Phenylpyrazole derivatives |
| CA2706328C (en) | 2007-11-20 | 2016-04-19 | Janssen Pharmaceutica N.V. | Cycloalkyloxy- and heterocycloalkyloxypyridine compounds as modulators of the histamine h3 receptor |
| EP2222650A1 (en) * | 2007-11-20 | 2010-09-01 | Janssen Pharmaceutica, N.V. | Substituted pyrazinyl amide compounds as modulators of the histamine h3 receptor |
| WO2009067406A1 (en) * | 2007-11-20 | 2009-05-28 | Janssen Pharmaceutica N.V. | Substituted pyridyl amide compounds as modulators of the histamine h3 receptor |
| CN102256963B (zh) | 2008-12-19 | 2014-06-11 | 贝林格尔.英格海姆国际有限公司 | 作为ccr2受体拮抗剂用于治疗炎症、哮喘和copd的环状嘧啶-4-甲酰胺 |
| TW201039822A (en) | 2009-02-06 | 2010-11-16 | Taisho Pharmaceutical Co Ltd | Dihydroquinolinone derivatives |
| PL2513093T3 (pl) | 2009-12-17 | 2015-03-31 | Centrexion Therapeutics Corp | Nowi antagoniści receptora CCR2 i ich zastosowanie |
| AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
| AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
| US9133123B2 (en) | 2010-04-23 | 2015-09-15 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
| WO2011141477A1 (en) | 2010-05-12 | 2011-11-17 | Boehringer Ingelheim International Gmbh | New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments |
| JP2013526507A (ja) | 2010-05-12 | 2013-06-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規ｃｃｒ２受容体アンタゴニスト、その製造方法及び薬物としてのその使用 |
| JP5647339B2 (ja) | 2010-05-17 | 2014-12-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｃｒ２アンタゴニスト及びこれらの使用 |
| WO2011147772A1 (en) | 2010-05-25 | 2011-12-01 | Boehringer Ingelheim International Gmbh | Ccr2 receptor antagonists |
| JP5721242B2 (ja) | 2010-06-01 | 2015-05-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規ｃｃｒ２アンタゴニスト |
| US12201676B2 (en) | 2011-03-18 | 2025-01-21 | Dr Healthcare España, S.L. | Composition comprising diamine oxidase for use in the treatment or prevention of fibromyalgia or chronic fatigue syndrome |
| JP2014527511A (ja) | 2011-06-24 | 2014-10-16 | アムジエン・インコーポレーテツド | Ｔｒｐｍ８拮抗剤及び治療におけるそれらの使用 |
| EP2723718A1 (en) | 2011-06-24 | 2014-04-30 | Amgen Inc. | Trpm8 antagonists and their use in treatments |
| EP2731941B1 (en) | 2011-07-15 | 2019-05-08 | Boehringer Ingelheim International GmbH | Novel and selective ccr2 antagonists |
| CA2858342A1 (en) | 2011-12-08 | 2013-06-13 | Taisho Pharmaceutical Co., Ltd. | Phenylpyrrole derivative |
| TW201343636A (zh) | 2011-12-27 | 2013-11-01 | 大正製藥股份有限公司 | 苯基三唑衍生物 |
| ES2426539B1 (es) * | 2012-04-18 | 2014-09-09 | Dr Healthcare España, S. L. | Uso de la diaminooxidasa para el tratamiento o la prevención del trastorno por deficit de atencion con hiperactividad (adhd) |
| US8952009B2 (en) | 2012-08-06 | 2015-02-10 | Amgen Inc. | Chroman derivatives as TRPM8 inhibitors |
| HUP1300139A2 (en) | 2013-03-06 | 2014-09-29 | Richter Gedeon Nyrt | Phenoxypiperidine h3 antagonists |
| EP3317270B1 (en) | 2015-07-02 | 2020-05-13 | Centrexion Therapeutics Corporation | (4-((3r,4r)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2r,6s)-6-(p-tolyl)tetrahydro-2h-pyran-2-yl)methylamino)pyrimidin-4yl)methanone citrate |
| ES2928164T3 (es) | 2015-10-19 | 2022-11-15 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| HUE060680T2 (hu) | 2015-11-19 | 2023-04-28 | Incyte Corp | Heterociklusos vegyületek mint immunmodulátorok |
| DK3394033T3 (da) | 2015-12-22 | 2021-01-04 | Incyte Corp | Heterocykliske forbindelser som immunmodulatorer |
| MA44860A (fr) | 2016-05-06 | 2019-03-13 | Incyte Holdings Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
| WO2017205464A1 (en) | 2016-05-26 | 2017-11-30 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| SG11201811414TA (en) | 2016-06-20 | 2019-01-30 | Incyte Corp | Heterocyclic compounds as immunomodulators |
| CN109476645A (zh) | 2016-07-14 | 2019-03-15 | 辉瑞大药厂 | 作为vanin-1酶抑制剂的新的嘧啶甲酰胺 |
| ES2930092T3 (es) | 2016-07-14 | 2022-12-07 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| EP3504198B1 (en) | 2016-08-29 | 2023-01-25 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| US20180179179A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| CA3047991A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Bicyclic heteroaromatic compounds as immunomodulators |
| EP3558989B1 (en) | 2016-12-22 | 2021-04-14 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
| MD3558990T2 (ro) | 2016-12-22 | 2023-02-28 | Incyte Corp | Derivați tetrahidro imidazo[4,5-c]piridină ca inductori de internalizare a PD-L1 |
| MA47123A (fr) | 2016-12-22 | 2021-03-17 | Incyte Corp | Dérivés de benzooxazole en tant qu'mmunomodulateurs |
| US10669271B2 (en) | 2018-03-30 | 2020-06-02 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| LT3790877T (lt) | 2018-05-11 | 2023-05-10 | Incyte Corporation | Tetrahidro-imidazo[4,5-c]piridino dariniai kaip pd-l1 imunomoduliatoriai |
| MA52850B1 (fr) * | 2018-05-31 | 2025-03-28 | Suven Life Sciences Limited | Méthode de traitement avec un agoniste inverse du récepteur de l'histamine-3 |
| HU231335B1 (hu) * | 2019-05-31 | 2023-01-28 | Richter Gedeon Nyrt. | Szelektív hisztamin H3 receptor antagonista savaddíciós sók és eljárás előállításukra |
| TW202115059A (zh) | 2019-08-09 | 2021-04-16 | 美商英塞特公司 | Ｐｄ—１／ｐｄ—ｌ１抑制劑之鹽 |
| EP4037773A1 (en) | 2019-09-30 | 2022-08-10 | Incyte Corporation | Pyrido[3,2-d]pyrimidine compounds as immunomodulators |
| PE20230407A1 (es) | 2019-11-11 | 2023-03-07 | Incyte Corp | Sales y formas cristalinas de un inhibidor de pd-1/pd-l1 |
| US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
| WO2022099071A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof |
| WO2022099075A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Crystalline form of a pd-1/pd-l1 inhibitor |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE817911C (de) | 1947-12-16 | 1951-10-22 | Chem Fab Tempelhof Preuss & Te | Verfahren zur Darstellung von in 6-Stellung basisch substituierten Pyridin-3-carbonsaeureamiden |
| BE726551A (enExample) | 1968-01-22 | 1969-06-16 | ||
| ES436109A1 (es) | 1974-04-04 | 1977-01-01 | Christiaens Sa A | Procedimiento para la preparacion de nuevos derivados de pi-ridina. |
| DE3366369D1 (en) | 1982-03-17 | 1986-10-30 | Smith Kline French Lab | Pyridine derivatives |
| GB8311443D0 (en) | 1983-04-27 | 1983-06-02 | Smith Kline French Lab | Chemical compounds |
| GB8320505D0 (en) | 1983-07-29 | 1983-09-01 | Smith Kline French Lab | Chemical compounds |
| GB8332091D0 (en) | 1983-12-01 | 1984-01-11 | Smith Kline French Lab | Chemical compounds |
| US4792547A (en) | 1985-12-26 | 1988-12-20 | Hokuriku Pharmaceutical Co., Ltd. | Pyrazine-2-carboxamide derivatives useful in treating allergic disease |
| US5201932A (en) * | 1989-09-22 | 1993-04-13 | Basf Aktiengesellschaft | Carboxamides |
| GB9025828D0 (en) * | 1990-11-28 | 1991-01-09 | Shell Int Research | Herbicidal carboxamide derivatives |
| JP3354271B2 (ja) * | 1993-02-25 | 2002-12-09 | 三共株式会社 | ピリジルオキシアミド誘導体 |
| EP0761654B1 (en) | 1995-08-24 | 2003-06-18 | Basf Aktiengesellschaft | Isoxazole- and isothiazole-5-carboxamide derivatives, their preparation and their use as herbicides |
| WO1997024329A1 (en) * | 1995-12-28 | 1997-07-10 | Kureha Kagaku Kogyo Kabushiki Kaisha | Process for producing pyridinecarboxamides or thiocarboxamides |
| TNSN97092A1 (ar) * | 1996-09-18 | 1999-12-31 | Agouron Pharma | مثبطات انزيم بروتيني فلزي وتركيبات صيدلانية تحتوي على تلك المثبتطات واستخدامها الصيدلاني وطرق ومركبات وسيطة مفيدة لتحضير التركيبات المذكورة. |
| WO2000050391A1 (en) | 1999-02-26 | 2000-08-31 | Merck & Co., Inc. | Novel sulfonamide compounds and uses thereof |
| DK1178973T3 (da) * | 1999-05-21 | 2006-05-08 | Biovitrum Ab | Pyrazinyl-piperazin-forbindelser, deres anvendelse og fremstilling |
| US6399607B1 (en) | 1999-07-02 | 2002-06-04 | Research Foundation-State University Of New York | Aminomethylene amide analogs of pyrazinamide with intracellular antimycobacterial activity against pyrazinamide-resistant mycobacteria combined with a rifamycin |
| DE10023492A1 (de) | 2000-05-09 | 2001-11-22 | Schering Ag | Aza- und Polyazanthranylamide und deren Verwendung als Arzneimittel |
| AU2001284733B2 (en) | 2000-08-08 | 2006-11-02 | Ortho-Mcneil Pharmaceutical, Inc. | Non-imidazole aryloxyalkylamines as H3 receptor ligands |
| US6645990B2 (en) * | 2000-08-15 | 2003-11-11 | Amgen Inc. | Thiazolyl urea compounds and methods of uses |
| US6995162B2 (en) * | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| WO2002100399A1 (en) * | 2001-06-12 | 2002-12-19 | Elan Pharmaceuticals, Inc. | Macrocycles useful in the treatment of alzheimer's disease |
| BR0210030A (pt) | 2001-06-15 | 2004-08-10 | Yamanouchi Pharma Co Ltd | Derivado de fenilpiridinacarbonilpiperazina |
| AU2002344951A1 (en) | 2001-07-02 | 2003-01-21 | Boehringer Ingelheim International Gmbh | Substituted piperazine and diazepanes as histamine h3 receptor agonists |
| US7208497B2 (en) * | 2001-07-02 | 2007-04-24 | Novo Nordisk A/S | Substituted piperazines and diazepanes |
| AU2002363174B2 (en) * | 2001-11-01 | 2008-09-25 | Janssen Pharmaceutica N.V. | Amide derivatives as glycogen synthase kinase 3-beta inhibitors |
| MXPA04004178A (es) * | 2001-11-01 | 2004-09-06 | Janssen Pharmaceutica Nv | Heteroarilaminas como inhibidores de glucogeno cintasa cinasa 3beta. |
| AU2003203148A1 (en) * | 2002-02-05 | 2003-09-02 | High Point Pharmaceuticals, Llc | Novel aryl- and heteroarylpiperazines |
| GB0206219D0 (en) | 2002-03-15 | 2002-05-01 | Ferring Bv | Non-Peptide GnRH antagonists |
| AU2003226094A1 (en) | 2002-03-27 | 2003-10-13 | Smithkline Beecham Corporation | Compounds and methods |
| US20040014744A1 (en) * | 2002-04-05 | 2004-01-22 | Fortuna Haviv | Substituted pyridines having antiangiogenic activity |
| GB0209715D0 (en) * | 2002-04-27 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
| EP1388535A1 (en) | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Acylated arylcycloalkylamines and their use as pharmaceuticals |
| US20040110802A1 (en) | 2002-08-23 | 2004-06-10 | Atli Thorarensen | Antibacterial benzoic acid derivatives |
| GB0224084D0 (en) * | 2002-10-16 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
| AU2003274053A1 (en) * | 2002-10-22 | 2004-05-13 | Glaxo Group Limited | Aryloxyalkylamine derivates as h3 receptor ligands |
| ATE449766T1 (de) * | 2002-10-23 | 2009-12-15 | Janssen Pharmaceutica Nv | Piperazinyl- und diazapanylbenzamide und- benzothioamide |
| US7332508B2 (en) | 2002-12-18 | 2008-02-19 | Novo Nordisk A/S | Substituted homopiperidine, piperidine or pyrrolidine derivatives |
| EP1642898B1 (en) * | 2003-06-27 | 2013-03-27 | Msd K.K. | Heteroaryloxy nitrogenous saturated heterocyclic derivative |
| DE602004026068D1 (de) | 2003-07-29 | 2010-04-29 | High Point Pharmaceuticals Llc | Pyridazinyl-piperazine und deren verwendung als histamin-h3-rezeptorliganden |
| WO2005023247A1 (en) * | 2003-09-03 | 2005-03-17 | Smithkline Beecham Corporation | Compounds and methods |
| GB0324159D0 (en) | 2003-10-15 | 2003-11-19 | Glaxo Group Ltd | Novel compounds |
| CA2561791A1 (en) * | 2004-03-31 | 2005-10-20 | Janssen Pharmaceutica, N.V. | Non-imidazole heterocyclic compounds |
| KR101336106B1 (ko) * | 2005-09-16 | 2013-12-05 | 얀센 파마슈티카 엔.브이. | 히스타민 ｈ3 수용체의 조절제로서 사이클로프로필 아민 |
| AU2006331882A1 (en) * | 2005-12-21 | 2007-07-05 | Schering Corporation | Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists |
| CA2645731A1 (en) * | 2006-03-15 | 2007-09-27 | Wyeth | N-substituted-azacyclylamines as histamine-3 antagonists |
| EA015555B1 (ru) * | 2006-05-30 | 2011-08-30 | Янссен Фармацевтика Н.В. | Замещенные пиридиламидные соединения в качестве модуляторов гистаминового h-рецептора |
| AU2007265238A1 (en) * | 2006-06-29 | 2008-01-03 | Janssen Pharmaceutica N.V. | Substituted benzamide modulators of the histamine H3 receptor |
-
2005
- 2005-03-31 CA CA002561791A patent/CA2561791A1/en not_active Abandoned
- 2005-03-31 EP EP05735453A patent/EP1761496A2/en not_active Withdrawn
- 2005-03-31 MX MXPA06011414A patent/MXPA06011414A/es active IP Right Grant
- 2005-03-31 WO PCT/US2005/010570 patent/WO2005097751A2/en not_active Ceased
- 2005-03-31 US US11/095,398 patent/US7423147B2/en active Active
- 2005-03-31 AU AU2005230902A patent/AU2005230902A1/en not_active Abandoned
- 2005-03-31 JP JP2007506483A patent/JP2007531753A/ja not_active Withdrawn
- 2005-03-31 CN CNA2005800176690A patent/CN1972914A/zh active Pending
-
2008
- 2008-08-06 US US12/186,927 patent/US20080306066A1/en not_active Abandoned
-
2009
- 2009-09-15 US US12/559,823 patent/US7947718B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007531753A5 (enExample) | ||
| JP3604399B2 (ja) | Ｎｏｓ阻害剤として有用な６−フェニルピリジル−２−アミン誘導体 | |
| RU2632900C2 (ru) | Гетероциклические амины и их применение | |
| RU2566827C2 (ru) | Пиколинамидные и пиримидин-4-карбоксамидные соединения, способ их получения и фармацевтическая композиция, включающая их | |
| US7718808B2 (en) | Thiazole derivatives | |
| JP2007531753A (ja) | 非イミダゾール系複素環式化合物 | |
| JP2020521730A5 (enExample) | ||
| Patil et al. | Pyridine and its biological activity: a review | |
| US20120309742A1 (en) | Use of metabotropic glutamate receptors | |
| HRP20141190T1 (hr) | Disupstituirani derivati piridina kao antikancerogena sredstva | |
| RU2007146270A (ru) | Гетероциклические ингибиторы hh-сигнального каскада, лекарственные композиции на их основе и способ лечения заболеваний, связанных с абберантной активностью hh сигнальной системы | |
| US20090270413A1 (en) | Di-t-butylphenyl piperazines as calcium channel blockers | |
| WO2008028903A2 (en) | Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer | |
| EP2035005A2 (en) | Therapy using cytokine inhibitors | |
| JP2006510609A5 (enExample) | ||
| RU2001125893A (ru) | Производные 3-фенилпиридина и их применение в качестве антагонистов рецептора NK-1 | |
| PT2041093E (pt) | Derivados de piperazinilo úteis no tratamento de doenças mediadas pelo receptor gpr38 | |
| JP2006526596A5 (enExample) | ||
| JP2014518281A (ja) | 電位依存性ナトリウムチャネル遮断薬 | |
| JP2007531755A5 (enExample) | ||
| JPH02134368A (ja) | 新規なピリジル‐およびピリミジル誘導体 | |
| HRP20010862A2 (en) | New pharmaceutical combinations for nos inhibitors | |
| JP2011500629A (ja) | 神経ペプチドｙ２受容体のモジュレーターとしての置換ピペラジンおよびピペリジン | |
| JP2006528624A (ja) | Ｐｄｅ４阻害剤として有用なニコチンアミド誘導体 | |
| Kuo et al. | Synthesis and Structure− Activity Relationships of Pyrazine-Pyridine Biheteroaryls as Novel, Potent, and Selective Vascular Endothelial Growth Factor Receptor-2 Inhibitors |